The use of biologic therapies in the treatment of rheumatoid arthritis

Current Pharmaceutical Biotechnology

Volumn 15, Issue 6, 2014, Pages 542-548

  Wang, Dashan ^a   Li, Yan ^b   Liu, Yuan ^b   Shi, Guixiu ^b  

^a Shandong Medical College   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

Biologic therapy; Cell targeted therapy; Cytokine targeted therapy; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; B7 ANTIGEN; BIOLOGICAL PRODUCT; CD28 ANTIGEN; CD86 ANTIGEN; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 20; INTERLEUKIN 23 ANTIBODY; INTERLEUKIN 6; IXEKIZUMAB; MAVRILIMUMAB; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SECUKINUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; USTEKINUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; BIOLOGICAL THERAPY; DRUG EFFICACY; DRUG SAFETY; HUMAN; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SIDE EFFECT; ARTHRITIS, RHEUMATOID;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; HUMANS;

EID: 84907174441     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920101506140910150612     Document Type: Article

References (99)

1. Goronzy, J. J.; Weyand, C. M. Rheumatoid arthritis. Immunol. Rev., 2005, 204, 55-73.
2. Gabriel, S. E.; Michaud, K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthr. Res. Ther., 2009, 11(3), 229.
3. Scott, D. L.; Wolfe, F.; Huizinga, T. W. Rheumatoid arthritis. Lancet, 2010, 376(9746), 1094-1108.
4. Polido-Pereira, J.; Vieira-Sousa, E.; Fonseca, J. E. Rheumatoid arthritis: What is refractory disease and how to manage it? Autoimmun. Rev., 2011, 10(11), 707-713.
5. Pablos, J. L.; Canete, J. D. Immunopathology of rheumatoid arthritis. Curr. Top. Med. Chem., 2013, 13(6), 705-711.
6. Firth, J.; Critchley, S. Treating to target in rheumatoid arthritis: biologic therapies. Br. J. Nurs., 2011, 20(20), 1284, 1287-8, 1290-1.
7. Canete, J. D.; Pablos, J. L. Biologic therapy in rheumatoid arthritis. Curr. Top. Med. Chem., 2013, 13(6), 752-759.
8. Atzeni, F.; Sarzi-Puttini, P.; Gorla, R.; Marchesoni, A.; Caporali, R. Switching rheumatoid arthritis treatments: An update. Autoimmun. Rev., 2011, 10(7), 397-403.
9. Breedveld, F. C.; Combe, B. Understanding emerging treatment paradigms in rheumatoid arthritis. Arthritis Res. Ther., 2011, 13(Suppl 1), S3.
10. Richardson, S.; Isaacs, J. Novel immunotherapies for rheumatoid arthritis. Clin. Med., 2013, 13(4), 391-394.
11. Scott, D. L. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin. Pharmacol. Ther., 2012, 91(1), 30-43.
12. Meier, F. M.; Frerix, M.; Hermann, W.; Muller-Ladner, U. Current immunotherapy in rheumatoid arthritis. Immunotherapy, 2013, 5(9), 955-974.
13. McInnes, I. B.; Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol., 2007, 7(6), 429-442.
14. rd. The pathogenesis of rheumatoid arthritis: Pivotal cytokines involved in bone degradation and inflammation. J. Rheumatol. Suppl., 2002, 65, 3-9.
15. Choy, E. H.; Panayi, G. S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med., 2001, 344(12), 907-916.
16. Ma, X.; Xu, S. TNF inhibitor therapy for rheumatoid arthritis. Biomed. Rep., 2013, 1(2), 177-184.
17. Smolen, J. S.; Emery, P. Infliximab: 12 years of experience. Arthritis Res. Ther., 2011, 13(Suppl 1), S2.
18. Thorne, C.; Bensen, W. G.; Choquette, D.; Chow, A.; Khraishi, M.; Atkins, C. J.; Kelsall, J. T.; Lehman, A. J.; Shawi, M.; Khalil, H.; Nantel, F.; Rampakakis, E.; Sampalis, J. S.; Otawa, S. Effectiveness and safety of infliximab in rheumatoid arthritis: Analysis from a Canadian multicentre prospective observational registry. Arthritis Care Res., (Hoboken), 2014.
19. Blumenauer, B.; Judd, M.; Wells, G.; Burls, A.; Cranney, A.; Hochberg, M.; Tugwell, P. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev., 2002, (3), CD003785.
20. Hunt, L.; Emery, P. Etanercept in the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther., 2013, 13(10), 1441-1450.
21. Alldred, A. Etanercept in rheumatoid arthritis. Expert Opin. Pharmacother., 2001, 2(7), 1137-1148.
22. Scott, D. L. Etanercept in arthritis. Int. J. Clin. Pract., 2005, 59(1), 114-118.
23. Voulgari, P. V.; Kaltsonoudis, E.; Papagoras, C.; Drosos, A. A. Adalimumab in the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther., 2012, 12(12), 1679-1686.
24. Hoff, M.; Kvien, T. K.; Kalvesten, J.; Elden, A.; Kavanaugh, A.; Haugeberg, G. Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study. BMC Musculoskelet. Disord., 2011, 12, 54.
25. Machado, M. A.; Maciel, A. A.; de Lemos, L. L.; Costa, J. O.; Kakehasi, A. M.; Andrade, E. I.; Cherchiglia, M. L.; Acurcio Fde, A. Adalimumab in rheumatoid arthritis treatment: A systematic review and meta-analysis of randomized clinical trials. Rev. Bras. Reumatol., 2013, 53(5), 419-430.
26. Zidi, I.; Bouaziz, A.; Mnif, W.; Bartegi, A.; Al-Hizab, F. A.; Amor, N. B. Golimumab therapy of rheumatoid arthritis: an overview. Scand. J. Immunol., 2010, 72(2), 75-85.
27. Emery, P.; Fleischmann, R.; van der Heijde, D.; Keystone, E. C.; Genovese, M. C.; Conaghan, P. G.; Hsia, E. C.; Xu, W.; Baratelle, A.; Beutler, A.; Rahman, M. U. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum., 2011, 63(5), 1200-1210.
28. Chovel-Sella, A.; Karplus, R.; Sella, T.; Amital, H. Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis. Isr. Med. Assoc. J., 2012, 14(6), 390-394.
29. Horton, S.; Walsh, C.; Emery, P. Certolizumab pegol for the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther., 2012, 12(2), 235-249.
30. Mease, P. J. Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety. Rheumatology, (Oxford) 2011, 50(2), 261-270.
31. Markatseli, T. E.; Papagoras, C.; Nikoli, A.; Voulgari, P. V.; Drosos, A. A. Certolizumab for rheumatoid arthritis. Clin. Exp. Rheumatol., 2014.
32. Kay, J.; Calabrese, L. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology, (Oxford) 2004, 43(Suppl 3), iii2-iii9.
33. Schiff, M. H. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann. Rheum. Dis., 2000, 59(Suppl 1), i103-8.
34. Mertens, M.; Singh, J. A. Anakinra for rheumatoid arthritis. Cochrane Database Syst. Rev., 2009, (1), CD005121.
35. de La Mata Llord, J.; Gonzalez Crespo, R.; Maese Manzano, J. Treatment of rheumatoid arthritis with anakinra: a systematic review. Reumatol. Clin., 2007, 3(4), 153-158.
36. Mertens, M.; Singh, J. A. Anakinra for rheumatoid arthritis: A systematic review. J. Rheumatol., 2009, 36(6), 1118-1125.
37. Srirangan, S.; Choy, E. H. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther. Adv. Musculoskelet. Dis., 2010, 2(5), 247-256.
38. Hashizume, M.; Mihara, M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis, 2011, 2011, 765624.
39. Md Yusof, M. Y.; Emery, P. Targeting interleukin-6 in rheumatoid arthritis. Drugs, 2013, 73(4), 341-56.
40. Navarro-Millan, I.; Singh, J. A.; Curtis, J. R. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin. Ther., 2012, 34(4), 788-802 e3.
41. Smolen, J. S.; Schoels, M. M.; Nishimoto, N.; Breedveld, F. C.; Burmester, G. R.; Dougados, M.; Emery, P.; Ferraccioli, G.; Gabay, C.; Gibofsky, A.; Gomez-Reino, J. J.; Jones, G.; Kvien, T. K.; Murakami, M.; Betteridge, N.; Bingham, C. O., 3rd; Bykerk, V.; Choy, E. H.; Combe, B.; Cutolo, M.; Graninger, W.; Lanas, A.; Martin-Mola, E.; Montecucco, C.; Ostergaard, M.; Pavelka, K.; Rubbert-Roth, A.; Sattar, N.; Scholte-Voshaar, M.; Tanaka, Y.; Trauner, M.; Valentini, G.; Winthrop, K. L.; de Wit, M.; van der Heijde, D. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann. Rheum. Dis., 2013, 72(4), 482-92.
42. Ogata, A.; Tanaka, T. Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. Int. J. Rheumatol., 2012, 2012, 946048.
43. McInnes, I. B.; Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med., 2011, 365(23), 2205-2219.
44. Alzabin, S.; Williams, R. O. Effector T cells in rheumatoid arthritis: Lessons from animal models. FEBS Lett., 2011, 585(23), 3649-3659.
45. VanderBorght, A.; Geusens, P.; Raus, J.; Stinissen, P. The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies. Semin. Arthritis Rheum., 2001, 31(3), 160-175.
46. Jendro, M. C.; Ganten, T.; Matteson, E. L.; Weyand, C. M.; Goronzy, J. J. Emergence of oligoclonal T cell populations following therapeutic T cell depletion in rheumatoid arthritis. Arthritis Rheum., 1995, 38(9), 1242-1251.
47. Chen, L.; Flies, D. B. Molecular mechanisms of T cell costimulation and co-inhibition. Nat. Rev. Immunol., 2013, 13(4), 227-242.
48. Walunas, T. L.; Lenschow, D. J.; Bakker, C. Y.; Linsley, P. S.; Freeman, G. J.; Green, J. M.; Thompson, C. B.; Bluestone, J. A. CTLA-4 can function as a negative regulator of T cell activation. Immunity, 1994, 1(5), 405-413.
49. Alegre, M. L.; Fallarino, F. Mechanisms of CTLA-4-Ig in tolerance induction. Curr. Pharm. Des., 2006, 12(2), 149-160.
50. Goronzy, J. J.; Weyand, C. M. T-cell co-stimulatory pathways in autoimmunity. Arthritis Res. Ther., 2008, 10(Suppl 1), S3.
51. Keating, G. M. Abatacept: a review of its use in the management of rheumatoid arthritis. Drugs, 2013, 73(10), 1095-1119.
52. Genovese, M. C.; Pacheco, T. C.; Covarrubias, A.; Leon, G.; Mysler, E.; Keiserman, M.; Valente, R.; Nash, P.; Simon-Campos, J. A.; Box, J.; Legerton, C. W. 3rd; Nasonov, E.; Durez, P.; Delaet, I.; Teng, J.; Alten, R. Subcutaneous abatacept for the treatment of rheumatoid arthritis: Longterm data from the ACQUIRE trial. J. Rheumatol., 2014.
53. Schiff, M. Abatacept treatment for rheumatoid arthritis. Rheumatology, (Oxford) 2011, 50(3), 437-49.
54. Price, S. Experimental arthritis: A potential role for B-cell effects on lymph nodes in the pathogenesis of RA. Nat. Rev. Rheumatol., 2010, 6(7), 380.
55. Chaiamnuay, S.; Bridges, S. L., Jr. The role of B cells and autoantibodies in rheumatoid arthritis. Pathophysiology, 2005, 12(3), 203-216.
56. Nakken, B.; Munthe, L. A.; Konttinen, Y. T.; Sandberg, A. K.; Szekanecz, Z.; Alex, P.; Szodoray, P. B-cells and their targeting in rheumatoid arthritis-current concepts and future perspectives. Autoimmun. Rev., 2011, 11(1), 28-34.
57. Lee, Y. H.; Bae, S. C.; Song, G. G. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol. Int., 2011, 31(11), 1493-1499.
58. Leandro, M. J.; Becerra-Fernandez, E. B-cell therapies in established rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol., 2011, 25(4), 535-548.
59. Hernandez-Cruz, B.; Garcia-Arias, M.; Ariza, R.; Martin, M. E. Rituximab in rheumatoid arthritis: a systematic review of efficacy and safety. Reumatol. Clin., 2011, 7(5), 314-322.
60. Rubbert-Roth, A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology, (Oxford) 2012, 51(Suppl 5), v38-47.
61. Horton, S.; Buch, M. H.; Emery, P. Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations. Drug Healthc. Patient Saf., 2010, 2, 101-119.
62. Woodrick, R. S.; Ruderman, E. M. Safety of biologic therapy in rheumatoid arthritis. Nat. Rev. Rheumatol., 2011, 7(11), 639-652.
63. Furst, D. E.; Emery, P. Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatology, (Oxford) 2014.
64. Smolen, J. S.; van der Heijde, D.; Machold, K. P.; Aletaha, D.; Landewe, R. Proposal for a new nomenclature of diseasemodifying antirheumatic drugs. Ann. Rheum. Dis., 2014, 73(1), 3-5.
65. Reynolds, G.; Cooles, F. A.; Isaacs, J. D.; Hilkens, C. M. Emerging immunotherapies for rheumatoid arthritis. Hum. Vaccin. Immunother., 2014, 10(4).
66. Burmester, G. R.; Feist, E.; Dorner, T. Emerging cell and cytokine targets in rheumatoid arthritis. Nat. Rev. Rheumatol., 2014, 10(2), 77-88.
67. Azizi, G.; Jadidi-Niaragh, F.; Mirshafiey, A. Th17 Cells in Immunopathogenesis and treatment of rheumatoid arthritis. Int. J. Rheum. Dis., 2013, 16(3), 243-253.
68. Kirkham, B. W.; Kavanaugh, A.; Reich, K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunol., 2014, 141(2), 133-142.
69. Genovese, M. C.; Durez, P.; Richards, H. B.; Supronik, J.; Dokoupilova, E.; Aelion, J. A.; Lee, S. H.; Codding, C. E.; Kellner, H.; Ikawa, T.; Hugot, S.; Ligozio, G.; Mpofu, S. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: Phase II, Dose-finding, double-blind, randomized, placebocontrolled study. J. Rheumatol., 2014, 41(3), 414-421.
70. Genovese, M. C.; Greenwald, M.; Cho, C. S.; Berman, A.; Jin, L.; Cameron, G. S.; Benichou, O.; Xie, L.; Braun, D.; Berclaz, P. Y.; Banerjee, S. Phase 2 randomized study of subcutaneous ixekizumab, an Anti-IL-17 monoclonal antibody, in biologic-naive or TNF-IR patients with rheumatoid arthritis. Arthritis Rheumatol., 2014.
71. Ma, Y.; Pope, R. M. The role of macrophages in rheumatoid arthritis. Curr. Pharm. Des., 2005, 11(5), 569-580.
72. Cornish, A. L.; Campbell, I. K.; McKenzie, B. S.; Chatfield, S.; Wicks, I. P. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat. Rev. Rheumatol., 2009, 5(10), 554-559.
73. Di Franco, M.; Gerardi, M. C.; Lucchino, B.; Conti, F. Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis. Core Evid., 2014, 9, 41-48.
74. Burmester, G. R.; Weinblatt, M. E.; McInnes, I. B.; Porter, D.; Barbarash, O.; Vatutin, M.; Szombati, I.; Esfandiari, E.; Sleeman, M. A.; Kane, C. D.; Cavet, G.; Wang, B.; Godwood, A.; Magrini, F. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann. Rheum. Dis., 2013, 72(9), 1445-1452.
75. Pope, R. M.; Shahrara, S. Possible roles of IL-12-family cytokines in rheumatoid arthritis. Nat. Rev. Rheumatol., 2013, 9(4), 252-256.
76. Rong, C.; Hu, W.; Wu, F. R.; Cao, X. J.; Chen, F. H. Interleukin-23 as a potential therapeutic target for rheumatoid arthritis. Mol. Cell Biochem., 2012, 361(1-2), 243-248.
77. Weitz, J. E.; Ritchlin, C. T. Ustekinumab: targeting the IL-17 pathway to improve outcomes in psoriatic arthritis. Expert Opin. Biol. Ther., 2014, 14(4), 515-526.
78. Kragstrup, T. W.; Otkjaer, K.; Holm, C.; Jorgensen, A.; Hokland, M.; Iversen, L.; Deleuran, B. The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy. Cytokine, 2008, 41(1), 16-23.
79. Hsu, Y. H.; Chang, M. S. Interleukin-20 antibody is a potential therapeutic agent for experimental arthritis. Arthritis Rheum., 2010, 62(11), 3311-3321.
80. Geusens, P. The role of RANK ligand/osteoprotegerin in rheumatoid arthritis. Ther. Adv. Musculoskelet. Dis., 2012, 4(4), 225-233.
81. Neumann, E.; Gay, S.; Muller-Ladner, U. The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. Arthritis Rheum., 2005, 52(10), 2960-2967.
82. Cohen, S. B.; Dore, R. K.; Lane, N. E.; Ory, P. A.; Peterfy, C. G.; Sharp, J. T.; van der Heijde, D.; Zhou, L.; Tsuji, W.; Newmark, R. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum., 2008, 58(5), 1299-1309.
83. Xu, Z.; Bouman-Thio, E.; Comisar, C.; Frederick, B.; Van Hartingsveldt, B.; Marini, J. C.; Davis, H. M.; Zhou, H. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br. J. Clin. Pharmacol., 2011, 72(2), 270-281.
84. Genovese, M. C.; Fleischmann, R.; Furst, D.; Janssen, N.; Carter, J.; Dasgupta, B.; Bryson, J.; Duncan, B.; Zhu, W.; Pitzalis, C.; Durez, P.; Kretsos, K. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: Outcomes of a randomised Phase IIb study. Ann. Rheum. Dis., 2014.
85. Huizinga, T. W.; Fleischmann, R. M.; Jasson, M.; Radin, A. R.; van Adelsberg, J.; Fiore, S.; Huang, X.; Yancopoulos, G. D.; Stahl, N.; Genovese, M. C. Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann. Rheum. Dis., 2013.
86. Tak, P. P.; Mease, P. J.; Genovese, M. C.; Kremer, J.; Haraoui, B.; Tanaka, Y.; Bingham, C. O., 3rd; Ashrafzadeh, A.; Travers, H.; Safa-Leathers, S.; Kumar, S.; Dummer, W. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum., 2012, 64(2), 360-370.
87. Stohl, W.; Gomez-Reino, J.; Olech, E.; Dudler, J.; Fleischmann, R. M.; Zerbini, C. A.; Ashrafzadeh, A.; Grzeschik, S.; Bieraugel, R.; Green, J.; Francom, S.; Dummer, W. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: The phase III FILM trial. Ann. Rheum. Dis., 2012, 71(8), 1289-1296.
88. Harigai, M.; Tanaka, Y.; Maisawa, S. Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: a placebo-controlled double-blind parallel-group study. J. Rheumatol., 2012, 39(3), 486-495.
89. Rigby, W.; Tony, H. P.; Oelke, K.; Combe, B.; Laster, A.; von Muhlen, C. A.; Fisheleva, E.; Martin, C.; Travers, H.; Dummer, W. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum., 2012, 64(2), 350-359.
90. Emery, P.; Rigby, W.; Tak, P. P.; Dorner, T.; Olech, E.; Martin, C.; Millar, L.; Travers, H.; Fisheleva, E. Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program. PLoS One, 2014, 9(2), e87379.
91. Kurrasch, R.; Brown, J. C.; Chu, M.; Craigen, J.; Overend, P.; Patel, B.; Wolfe, S.; Chang, D. J. Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics. J. Rheumatol., 2013, 40(7), 1089-1096.
92. Taylor, P. C.; Quattrocchi, E.; Mallett, S.; Kurrasch, R.; Petersen, J.; Chang, D. J. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann. Rheum. Dis., 2011, 70(12), 2119-2125.
93. Mackay, F.; Browning, J. L. BAFF: a fundamental survival factor for B cells. Nat. Rev. Immunol., 2002, 2(7), 465-475.
94. Rauch, M.; Tussiwand, R.; Bosco, N.; Rolink, A. G. Crucial role for BAFF-BAFF-R signaling in the survival and maintenance of mature B cells. PLoS One, 2009, 4(5), e5456.
95. Dubey, A. K.; Handu, S. S.; Dubey, S.; Sharma, P.; Sharma, K. K.; Ahmed, Q. M. Belimumab: first targeted biological treatment for systemic lupus erythematosus. J. Pharmacol. Pharmacother., 2011, 2(4), 317-319.
96. Stohl, W.; Merrill, J. T.; McKay, J. D.; Lisse, J. R.; Zhong, Z. J.; Freimuth, W. W.; Genovese, M. C. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. J. Rheumatol., 2013, 40(5), 579-589.
97. Combe, B.; van Vollenhoven, R. Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples. Ann. Rheum. Dis., 2013, 72(9), 1433-1435.
98. Genovese, M. C.; Bojin, S.; Biagini, I. M.; Mociran, E.; Cristei, D.; Mirea, G.; Georgescu, L.; Sloan-Lancaster, J. Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial. Arthritis Rheum., 2013, 65(4), 880-889.
99. Genovese, M. C.; Fleischmann, R. M.; Greenwald, M.; Satterwhite, J.; Veenhuizen, M.; Xie, L.; Berclaz, P. Y.; Myers, S.; Benichou, O. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann. Rheum. Dis., 2013, 72(9), 1461-1468.